

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 10-Q**

**(Mark One)**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2023

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 001-32587



**ALTIMMUNE, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**910 Clopper Road Suite 201S, Gaithersburg, Maryland**  
(Address of Principal Executive Offices)

**20-2726770**  
(I.R.S. Employer  
Identification No.)

**20878**  
(Zip Code)

**(240) 654-1450**

(Registrant's Telephone Number, Including Area Code)

**Securities registered pursuant to Section 12(b) of the Act:**

<i>Title of each class</i>	<i>Trading Symbol(s)</i>	<i>Name of each exchange on which registered</i>
Common stock, par value \$0.0001 per share	ALT	The NASDAQ Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No

As of November 3, 2023 there were 53,728,871 shares of the registrant's common stock, par value \$0.0001 per share, outstanding.

**ALTIMMUNE, INC.**  
**TABLE OF CONTENTS**

	<u>Page</u>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
<b><u>Item 1. Financial Statements</u></b>	1
<u>Consolidated Balance Sheets as of September 30, 2023 (unaudited) and December 31, 2022</u>	1
<u>Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 (unaudited)</u>	2
<u>Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended September 30, 2023 and 2022 (unaudited)</u>	3
<u>Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 (unaudited)</u>	5
<u>Notes to Consolidated Financial Statements (unaudited)</u>	6
<b><u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	13
<b><u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u></b>	20
<b><u>Item 4. Controls and Procedures</u></b>	20
<b><u>PART II. OTHER INFORMATION</u></b>	
<b><u>Item 1. Legal Proceedings</u></b>	20
<b><u>Item 1A. Risk Factors</u></b>	20
<b><u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	20
<b><u>Item 3. Defaults Upon Senior Securities</u></b>	20
<b><u>Item 4. Mine Safety Disclosures</u></b>	21
<b><u>Item 5. Other Information</u></b>	21
<b><u>Item 6. Exhibits</u></b>	22
<u>Signatures</u>	23

---

**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements**

**ALTIMMUNE, INC.**  
**CONSOLIDATED BALANCE SHEETS**  
**(In thousands, except share and per-share amounts)**

	September 30, 2023 (Unaudited)	December 31, 2022
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 86,855	\$ 111,097
Restricted cash	41	34
Total cash, cash equivalents and restricted cash	86,896	111,131
Short-term investments	53,924	73,783
Accounts receivable	876	173
Income tax and R&D incentive receivables	3,653	2,368
Prepaid expenses and other current assets	7,615	5,358
Total current assets	152,964	192,813
Property and equipment, net	765	1,081
Indefinite-lived intangible asset	12,419	12,419
Other assets	425	615
Total assets	<u>\$ 166,573</u>	<u>\$ 206,928</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 3,046	\$ 4,804
Accrued expenses and other current liabilities	8,825	12,250
Total current liabilities	11,871	17,054
Other long-term liabilities	4,305	4,581
Total liabilities	16,176	21,635
Commitments and contingencies (Note 10)		
Stockholders' equity:		
Common stock, \$0.0001 par value; 200,000,000 shares authorized; 52,858,920 and 49,199,845 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	5	5
Additional paid-in capital	590,206	568,399
Accumulated deficit	(434,690)	(377,884)
Accumulated other comprehensive loss, net	(5,124)	(5,227)
Total stockholders' equity	150,397	185,293
Total liabilities and stockholders' equity	<u>\$ 166,573</u>	<u>\$ 206,928</u>

*The accompanying notes are an integral part of the unaudited consolidated financial statements.*

**ALTIMMUNE, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**  
**(Unaudited)**  
**(In thousands, except share and per-share amounts)**

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Revenues	\$ 362	\$ 2	\$ 389	\$ 42
Operating expenses:				
Research and development	18,388	20,262	48,890	51,359
General and administrative	4,514	4,492	13,805	13,329
Total operating expenses	22,902	24,754	62,695	64,688
Loss from operations	(22,540)	(24,752)	(62,306)	(64,646)
Other income (expense):				
Interest expense	(29)	(64)	(33)	(191)
Interest income	1,884	1,053	5,387	1,402
Other income (expense), net	14	50	146	185
Total other income (expense), net	1,869	1,039	5,500	1,396
Net loss before income taxes	(20,671)	(23,713)	(56,806)	(63,250)
Income tax expense (benefit)	—	(197)	—	(197)
Net loss	(20,671)	(23,516)	(56,806)	(63,053)
Other comprehensive income — unrealized gain (loss) on short-term investments	56	(143)	103	(263)
Comprehensive loss	\$ (20,615)	\$ (23,659)	\$ (56,703)	\$ (63,316)
Net loss per share, basic and diluted	\$ (0.39)	\$ (0.48)	\$ (1.10)	\$ (1.37)
Weighted-average common shares outstanding, basic and diluted	53,633,354	49,286,535	51,495,957	45,881,547

*The accompanying notes are an integral part of the unaudited consolidated financial statements.*

**ALTIMMUNE, INC.**  
**CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**  
**(Unaudited)**  
**(In thousands, except share amounts)**

	Common Stock		Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total Stockholders' Equity
	Shares	Amount				
<b>Balance at December 31, 2022</b>	49,199,845	\$ 5	\$ 568,399	\$ (377,884)	\$ (5,227)	\$ 185,293
Stock-based compensation	—	—	2,675	—	—	2,675
Exercise of stock options	19,303	—	61	—	—	61
Vesting of restricted stock awards including withholding, net	54,347	—	(484)	—	—	(484)
Issuance of common stock from Employee Stock Purchase Plan	13,215	—	135	—	—	135
Unrealized (loss) gain on short-term investments	—	—	—	—	126	126
Net loss	—	—	—	(20,074)	—	(20,074)
<b>Balance at March 31, 2023</b>	<u>49,286,710</u>	<u>\$ 5</u>	<u>\$ 570,786</u>	<u>\$ (397,958)</u>	<u>\$ (5,101)</u>	<u>\$ 167,732</u>
Stock-based compensation	—	\$ —	\$ 2,786	\$ —	\$ —	\$ 2,786
Vesting of restricted stock awards including withholding, net	6,320	—	(16)	—	—	(16)
Issuance of common stock in at-the-market offerings, net	3,364,631	—	13,352	—	—	13,352
Unrealized (loss) gain on short-term investments	—	—	—	—	(79)	(79)
Net loss	—	—	—	(16,061)	—	(16,061)
<b>Balance at June 30, 2023</b>	<u>52,657,661</u>	<u>\$ 5</u>	<u>\$ 586,908</u>	<u>\$ (414,019)</u>	<u>\$ (5,180)</u>	<u>\$ 167,714</u>
Stock-based compensation	—	\$ —	\$ 2,710	\$ —	\$ —	\$ 2,710
Vesting of restricted stock awards including withholding, net	1,261	—	(2)	—	—	(2)
Issuance of common stock in at-the-market offerings, net	171,653	—	510	—	—	510
Issuance of common stock from Employee Stock Purchase Plan	28,345	—	80	—	—	80
Unrealized loss on short-term investments	—	—	—	—	56	56
Net loss	—	—	—	(20,671)	—	(20,671)
<b>Balance at September 30, 2023</b>	<u>52,858,920</u>	<u>\$ 5</u>	<u>\$ 590,206</u>	<u>\$ (434,690)</u>	<u>\$ (5,124)</u>	<u>\$ 150,397</u>

*The accompanying notes are an integral part of the unaudited consolidated financial statements.*

**ALTIMMUNE, INC.**  
**CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**  
**(Unaudited)**  
**(In thousands, except share amounts)**

	Common Stock		Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total Stockholders' Equity
	Shares	Amount				
<b>Balance at December 31, 2021</b>	40,993,768	\$ 4	\$ 497,342	\$ (293,171)	\$ (5,040)	\$ 199,135
Stock-based compensation	—	—	2,033	—	—	2,033
Exercise of stock options	95,771	—	197	—	—	197
Vesting of restricted stock awards including withholding, net	17,568	—	(170)	—	—	(170)
Issuance of common stock from Employee Stock Purchase Plan	16,450	—	113	—	—	113
Issuance of common stock in at-the-market offerings, net	335,485	—	2,990	—	—	2,990
Issuance of common stock upon exercise of warrants	1,760,854	—	—	—	—	—
Net loss	—	—	—	(19,430)	—	(19,430)
<b>Balance at March 31, 2022</b>	<u>43,219,896</u>	<u>\$ 4</u>	<u>\$ 502,505</u>	<u>\$ (312,601)</u>	<u>\$ (5,040)</u>	<u>\$ 184,868</u>
Stock-based compensation	—	\$ —	\$ 2,048	\$ —	\$ —	\$ 2,048
Exercise of stock options	152,913	—	403	—	—	403
Vesting of restricted stock awards including withholding, net	(5,865)	—	(80)	—	—	(80)
Issuance of common stock in at-the-market offerings, net	2,157,717	1	21,346	—	—	21,347
Issuance of common stock related to contingent consideration liability	847,444	—	6,176	—	—	6,176
Unrealized (loss) gain on short-term investments	—	—	—	—	(120)	(120)
Net loss	—	—	—	(20,107)	—	(20,107)
<b>Balance at June 30, 2022</b>	<u>46,372,105</u>	<u>\$ 5</u>	<u>\$ 532,398</u>	<u>\$ (332,708)</u>	<u>\$ (5,160)</u>	<u>\$ 194,535</u>
Stock-based compensation	—	\$ —	\$ 2,128	\$ —	\$ —	\$ 2,128
Exercise of stock options	76,161	—	268	—	—	268
Vesting of restricted stock awards including withholding, net	(7,744)	—	(140)	—	—	(140)
Issuance of common stock in at-the-market offerings, net	2,711,013	—	31,829	—	—	31,829
Issuance of common stock from Employee Stock Purchase Plan	9,945	—	68	—	—	68
Other increase	157	—	—	—	—	—
Unrealized loss on short-term investments	—	—	—	—	(143)	(143)
Net loss	—	—	—	(23,516)	—	(23,516)
<b>Balance at September 30, 2022</b>	<u>49,161,637</u>	<u>\$ 5</u>	<u>\$ 566,551</u>	<u>\$ (356,224)</u>	<u>\$ (5,303)</u>	<u>\$ 205,029</u>

*The accompanying notes are an integral part of the unaudited consolidated financial statements.*

**ALTIMMUNE, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(Unaudited)**  
**(In thousands)**

	Nine Months Ended September 30,	
	2023	2022
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net loss	\$ (56,806)	\$ (63,053)
Adjustments to reconcile net loss to net cash used in operating activities:		
Change in fair value of contingent consideration liability	—	86
Stock-based compensation expense	8,171	6,209
Depreciation and amortization	(1,413)	31
Loss on foreign currency exchange	(134)	(183)
Changes in operating assets and liabilities:		
Accounts receivable	(704)	(204)
Prepaid expenses and other assets	(2,043)	3,204
Accounts payable	(1,758)	(615)
Accrued expenses and other liabilities	(3,306)	7,555
Income tax and R&D incentive receivables	(1,284)	1,690
Net cash used in operating activities	(59,277)	(45,280)
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Proceeds from sales and maturities of short-term investments	76,544	—
Purchases of short-term investments	(54,806)	(74,292)
Purchases of property and equipment, net	(47)	(88)
Net cash provided by (used in) investing activities	21,691	(74,380)
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Payments of deferred offering costs	(195)	—
Proceeds from issuance of common stock in at-the-market offerings, net	13,862	56,166
Proceeds from issuance of common stock from Employee Stock Purchase Plan	215	181
Payment of conditional economic incentive	(90)	—
Proceeds from exercises of stock options	61	868
Payments for tax withholding in share-based compensation	(502)	(391)
Net cash provided by financing activities	13,351	56,824
Net decrease in cash and cash equivalents and restricted cash	(24,235)	(62,836)
Cash, cash equivalents and restricted cash at beginning of period	111,131	190,335
Cash, cash equivalents and restricted cash at end of period	\$ 86,896	\$ 127,499
<b>SUPPLEMENTAL NON-CASH ACTIVITIES:</b>		
Fair value of common stock retired in exchange for issuance of common stock warrant	\$ —	\$ 6,176

*The accompanying notes are an integral part of the unaudited consolidated financial statements.*

**ALTIMMUNE, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(Unaudited)**

**1. Nature of Business and Basis of Presentation**

*Nature of Business*

Altimmune, Inc., headquartered in Gaithersburg, Maryland, United States, together with its subsidiaries (collectively, the “Company” or “Altimmune”) is a clinical stage biopharmaceutical company incorporated under the laws of the State of Delaware.

The Company is focused on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (“NASH”) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (“HepTcell™”). Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital, and has financed its operations through the issuance of common and preferred stock, long-term debt and proceeds from research grants and government contracts. The Company has not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales.

*Basis of Presentation*

The accompanying unaudited consolidated financial statements are prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2022 included in the Annual Report on Form 10-K which was filed with the SEC on February 28, 2023. In the opinion of management, the Company has prepared the accompanying unaudited consolidated financial statements on the same basis as the audited consolidated financial statements, and these consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of the interim periods presented. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year 2023 or any future years or periods.

The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

**2. Summary of Significant Accounting Policies**

During the nine months ended September 30, 2023, there have been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC, except for the recently adopted accounting standard for ASU No. 2016-13 as disclosed below.

*Use of Estimates*

The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not



limited to, the valuation of share-based awards, income taxes, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.

*Short-term Investments*

The Company’s short-term investments are comprised of U.S. Treasuries, corporate debt securities and certificates of deposit that have original maturities less than or equal to one year and are classified as available-for-sale (“AFS”) securities. Such securities are carried at estimated fair value, net of allowance for credit loss determined based on the Current Expected Credit Loss. Any unrealized holding gains or losses are reported as accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. In the event that the AFS security’s fair value is below the amortized cost and (i) the Company intends to sell the AFS security and (ii) the AFS security is required to be sold before recovery of the loss, the AFS security’s amortized cost base will be written down to its fair value and the loss will be recognized in the income statement. If the Company intends not to sell the AFS security and the AFS security is not required to be sold before recovery of the loss, the Company evaluates whether a portion of the unrealized loss is a result of credit loss. The portion of unrealized loss related to credit loss will be recorded as allowance for credit loss in the balance sheet with the corresponding credit loss in the income statement and the portion of unrealized loss not related to credit loss will be recognized in other comprehensive income (“OCI”). Dividend and interest income are recognized in other income when earned. The cost of securities sold is calculated using the specific identification method. The Company places all investments with government agencies, or corporate institutions whose debt is rated as investment grade. As of September 30, 2023, none of the unrealized losses on the Company’s short-term investments are a result of credit loss, and therefore, the unrealized losses were recognized in OCI.

*Income Taxes*

During the three and nine months ended September 30, 2022, the Company recorded a total of \$0.2 million income tax benefit related to interest received and receivable on income tax refunds. Other than the tax benefit related to interest, the Company did not record an income tax expense (benefit) for either of the three and nine months ended September 30, 2023 or 2022 due to a full valuation allowance. The Company calculates its quarterly income tax provision based on an estimated, annual effective tax rate applied to ordinary income (or loss) and other known items computed and recognized as they occur. The Company’s total provision is based on the United States statutory rate, increased by state and foreign taxes and reduced by a full valuation allowance on the Company’s deferred tax assets.

*Recently adopted accounting pronouncements*

In June 2016, the FASB issued ASU No. 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* (“ASU No. 2016-13”). ASU No. 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected and any unrealized loss relating to available-for-sale debt securities to be recorded through an allowance for credit losses. The Company adopted this new accounting standard on January 1, 2023 using a modified retrospective method. Adoption of this update did not have a material impact on the Company’s financial statements and related disclosures.

**3. Fair Value Measurements**

The Company’s assets measured at fair value on a recurring basis as of September 30, 2023 consisted of the following (in thousands):

	Fair Value Measurement at September 30, 2023			
	Total	Level 1	Level 2	Level 3
Assets:				
Cash equivalents - money market funds	\$ 82,102	\$ 82,102	\$ —	\$ —
Short-term investments	53,924	—	53,924	—
Total	\$ 136,026	\$ 82,102	\$ 53,924	\$ —

The Company's assets measured at fair value on a recurring basis as of December 31, 2022 consisted of the following (in thousands):

	Fair Value Measurement at December 31, 2022			
	Total	Level 1	Level 2	Level 3
<b>Assets:</b>				
Cash equivalents - money market funds	\$ 105,794	\$ 105,794	\$ —	\$ —
Short-term investments	73,783	—	73,783	—
Total	<u>\$ 179,577</u>	<u>\$ 105,794</u>	<u>\$ 73,783</u>	<u>\$ —</u>

Short-term investments have been initially valued at the transaction price and subsequently valued at the end of each reporting period utilizing third party pricing services or other market observable data (Level 2). The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value.

Short-term investments with quoted prices as of September 30, 2023 as shown below (in thousands):

	September 30, 2023			
	Amortized Cost	Unrealized (Loss) Gain	Credit loss	Market Value
United States treasury securities	\$ 9,857	\$ (7)	\$ —	\$ 9,850
Commercial paper and corporate debt securities	33,328	(53)	—	33,275
Asset backed securities	2,937	(12)	—	2,925
Agency debt securities	7,886	(12)	—	7,874
Total	<u>\$ 54,008</u>	<u>\$ (84)</u>	<u>\$ —</u>	<u>\$ 53,924</u>

Short-term investments with quoted prices as of December 31, 2022 as shown below (in thousands):

	December 31, 2022			
	Amortized Cost	Unrealized (Loss) Gain	Credit Loss	Market Value
United States treasury securities	\$ 15,868	\$ (86)	\$ —	\$ 15,782
Commercial paper and corporate debt securities	50,747	(71)	—	50,676
Asset backed securities	5,427	(35)	—	5,392
Agency debt securities	1,928	5	—	1,933
Total	<u>\$ 73,970</u>	<u>\$ (187)</u>	<u>\$ —</u>	<u>\$ 73,783</u>

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. Assets recorded at fair value on a non-recurring basis, such as property and equipment and intangible assets are recognized at fair value when they are impaired. During the nine months ended September 30, 2023 and year ended December 31, 2022, the Company had no significant assets or liabilities that were measured at fair value on a non-recurring basis.

#### 4. Operating Leases

The Company's operating leases consist of leases for office and laboratory space in the United States, which expire in April 2025. Rent expense under the Company's operating leases was \$0.1 million and \$0.4 million during the three and nine months ended September 30, 2023. During the three and nine months ended September 30, 2022, rent expense under the Company's operating leases was \$0.1 million and \$0.4 million, respectively. Rent expense includes short-term leases and variable lease costs that are not included in the lease obligation.

Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases.

[Table of Contents](#)

The office space lease provides for increases in future minimum annual rental payments as defined in the lease agreements. The office space lease also includes an option to renew the lease as of the end of the term. The Company has determined that the lease renewal option is not reasonably certain of being exercised.

The cash paid for operating lease liabilities for each of the nine months ended September 30, 2023 and 2022 was \$0.4 million.

Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):

	<u>September 30, 2023</u>	<u>December 31, 2022</u>
Operating lease obligations (see Note 5 and 6)	\$ 788	\$ 1,124
Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)	\$ 424	\$ 596
Weighted-average remaining lease term (years)	1.6	2.3
Weighted-average discount rate	7.2 %	7.2 %

## 5. Accrued Expenses

Accrued expenses and other current liabilities consist of the following (in thousands):

	<u>September 30, 2023</u>	<u>December 31, 2022</u>
Accrued professional services	\$ 313	\$ 276
Accrued payroll and employee benefits	2,427	2,955
Accrued research and development	5,537	7,295
Lease obligation, current portion (see Note 4)	485	452
Excess tax refund payable	—	1,169
Accrued interest and other	63	103
Total accrued expenses and other current liabilities	<u>\$ 8,825</u>	<u>\$ 12,250</u>

## 6. Other Long-Term Liabilities

The Company's other long-term liabilities are summarized as follows (in thousands):

	<u>September 30, 2023</u>	<u>December 31, 2022</u>
Research and development incentive credit	\$ 3,796	\$ 3,599
Lease obligation, long-term portion (see Note 4)	303	672
Conditional economic incentive grants	160	250
Other	46	60
Total other long-term liabilities	<u>\$ 4,305</u>	<u>\$ 4,581</u>

## 7. Common Stock

The Amended and Restated Certificate of Incorporation, as amended ("Charter"), authorizes the Company to issue 200,000,000 shares of common stock, par value \$0.0001 per share. As of September 30, 2023, the Company had 52,858,920 shares of common stock issued and outstanding.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.

The Charter also authorizes the Company to issue 1,000,000 shares of preferred stock, par value \$0.0001 per share. As of September 30, 2023, the Company had no shares of preferred stock issued and outstanding.

### *At-the-Market Offerings*

On February 28, 2023, the Company entered into an Equity Distribution Agreement (the “2023 Agreement”) with Evercore Group L.L.C., JMP Securities LLC and B. Riley Securities, Inc., serving as sales agents (the “Sales Agents”), with respect to an at-the-market offerings program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to \$150.0 million (the “Shares”) through the Sales Agents (the “2023 Offering”). All Shares offered and sold in the 2023 Offering will be issued pursuant to the Company’s Registration Statement on Form S-3ASR filed with the SEC on February 28, 2023, which was declared effective immediately, the prospectus supplement relating to the 2023 Offering filed with the SEC on February 28, 2023 and any applicable additional prospectus supplements related to the 2023 Offering that form a part of the Registration Statement. The Company capitalized approximately \$0.2 million of other offering costs which will offset the proceeds received from the shares sold under the 2023 Agreement. During the nine months ended September 30, 2023, the Company sold 3,536,284 shares of common stock under the 2023 Agreement resulting in approximately \$13.9 million in proceeds, net of \$0.4 million commission and other offering costs. As of September 30, 2023, \$135.7 million remained available to be sold under the 2023 Agreement. As of September 30, 2023, there was \$0.2 million in deferred offering costs included in prepaid expenses and other current assets on the accompanying consolidated balance sheets.

On February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 Agreement”) with Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents (the “2021 Sales Agents”), with respect to an at-the-market offerings program under which the Company offered and sold shares of its common stock, having an aggregate offering price of up to \$125.0 million (the “2021 Shares”) through the 2021 Sales Agents (the “2021 Offering”). All 2021 Shares offered and sold in the 2021 Offering were issued pursuant to the Company’s Registration Statement on Form S-3 filed with the SEC on December 31, 2020, which was declared effective on January 11, 2021, the prospectus supplement relating to the 2021 Offering filed with the SEC on February 25, 2021 and any applicable additional prospectus supplements related to the 2021 Offering that form a part of the Registration Statement. Under the 2021 Agreement, the Company sold 10,004,869 shares of common stock resulting in approximately \$121.0 million in proceeds, net of \$4.0 million commission and other offering costs. As of September 30, 2023, there were no remaining shares available under the 2021 Agreement.

### *Public Offering*

On July 16, 2020, the Company offered and sold (i) 3,369,564 shares of common stock, at a price to the public of \$23.00 per share, and (ii) pre-funded warrants of the Company to purchase 1,630,436 shares of common stock at an exercise price equal to \$0.0001 per share (the “Pre-Funded Warrants”), at a price to the public of \$22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of common stock, minus the exercise price of each Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of the Company’s common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to the Company.

The Company has assessed the Pre-Funded Warrants for appropriate equity or liability classification and determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability pursuant to ASC 480 and do not meet the definition of a derivative pursuant to FASB Accounting Standards Codification Topic 815, *Derivatives and Hedging* (“ASC 815”). The Pre-Funded Warrants are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the Pre-Funded Warrants were classified as equity and are accounted for as a component of additional paid-in capital at the time of issuance. On January 24, 2022, 760,870 of the Pre-Funded Warrants were exercised, resulting in the issuance of 760,870 shares of common stock. As of September 30, 2023, there were 869,566 remaining Pre-Funded Warrants unexercised. Subsequent to September 30, 2023, the remaining Pre-Funded Warrants were net cashless exercised, and currently no Pre-Funded Warrants remain available for exercise (see Note 11 Subsequent Events).

As of September 30, 2023, including the remaining 869,566 Pre-Funded Warrants, there were 1,015,166 outstanding warrants with a weighted-average exercise price of \$0.66 and weighted-average contractual term of 0.2 years.

## 8. Stock-Based Compensation

### Stock Options

The Company's stock option awards generally vest over four years and typically have a contractual life of ten years. As of September 30, 2023, there was \$17.9 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 2.7 years. During the nine months ended September 30, 2023, the Company granted 1,760,026 stock options with a weighted average exercise price of \$9.71 and per share weighted average grant date fair value of \$7.86.

Information related to stock options outstanding as of September 30, 2023 is as follows:

	Number of Stock Options	Weighted- Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In thousands)
Outstanding	5,079,329	\$ 9.31	5.9	\$ 239
Exercisable	2,260,984	\$ 8.81	5.8	\$ 200
Vested and expected to vest	4,769,311	\$ 9.28	5.9	\$ 235

### Restricted Stock Units (RSUs)

During the nine months ended September 30, 2023, the Company granted 319,700 shares of RSUs with a weighted average grant date fair value of \$13.20 which vest over four years. As of September 30, 2023, the Company had unvested RSUs of 618,543 shares with total unrecognized compensation expense of \$5.1 million, which the Company expects to recognize over a weighted average period of approximately 2.7 years. During the nine months ended September 30, 2023, the Company issued 61,928 shares of unrestricted common stock as a result of the vesting of 100,642 RSUs net of 38,714 shares of common stock withheld to satisfy tax withholding obligations.

### 2019 Employee Stock Purchase Plan (ESPP)

Under the ESPP, employees purchased 41,560 shares for \$0.2 million during the nine months ended September 30, 2023. During the nine months ended September 30, 2023 and 2022, the Company recognized compensation expense of \$0.1 million and \$0.2 million, respectively.

### Stock-based Compensation Expense

Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023 and 2022 as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Research and development	\$ 1,164	\$ 743	\$ 3,560	\$ 2,024
General and administrative	1,546	1,385	4,611	4,185
Total	\$ 2,710	\$ 2,128	\$ 8,171	\$ 6,209

## 9. Net Loss Per Share

Because the Company has reported a net loss attributable to common stockholders for the nine months ended September 30, 2023 and 2022, basic and diluted net loss per share attributable to common stockholders in each period are the same.

Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average numbers of shares of common stock outstanding for the period. Basic

shares outstanding includes the weighted average effect of the Company's outstanding pre-funded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock.

Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. As such, all unvested restricted stock, RSUs, common stock warrants, and stock options have been excluded from the computation of diluted weighted average shares outstanding because such securities would have an anti-dilutive impact for all periods presented.

Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, RSUs, common stock warrants, and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:

	Nine Months Ended September 30,	
	2023	2022
Common stock warrants	145,600	145,600
Common stock options	5,144,429	3,542,534
Restricted stock units	618,543	470,275
Restricted stock	—	13,454

## 10. Commitments and Contingencies

### *Spitfire Acquisition*

In July 2019, the Company entered into the Spitfire merger agreement to acquire all of the equity interests of Spitfire Pharma, Inc. ("Spitfire"). As part of the agreement, the Company is obligated to make payments of up to \$80.0 million upon the achievement of specified worldwide net sales of all products developed using the technology acquired from Spitfire Pharma Inc. (the "Sales Milestone") within ten years following the approval of a new drug application filed with the U. S. Food and Drug Administration (the "FDA").

The contingent payments related to the Sales Milestones are predominately cash-based payments accounted for under FASB Accounting Standards Codification Topic 450, *Contingencies*. Accordingly, the Company will recognize the Sales Milestones when the contingency is probable and the amount can be reasonably estimated.

### *Litigation*

The Company is a party in various contracts and subject to disputes, litigation, and potential claims arising in the ordinary course of business none of which are currently reasonably possible or probable of material loss.

## 11. Subsequent Events

On October 18, 2023, warrant holders exercised the remaining 869,566 Pre-Funded Warrants in a net cashless exercise and were issued 869,530 shares of common stock in a net cashless exercise (see Note 7 Common Stock).

In addition, in October 2023, 95,600 various other warrants with a weighted-average exercise price of \$5.31 expired unexercised. The only remaining outstanding 50,000 warrants have an exercise price of \$3.21 and have a maturity date of March 12, 2024.

## **Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our consolidated financial statements and related notes for the year ended December 31, 2022 included in our Annual Report on Form 10-K, which was filed with the SEC on February 28, 2023.*

*This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “may,” “will,” “should,” “could,” “target,” “strategy,” “intend,” “project,” “guidance,” “likely,” “usually,” “potential,” or the negative of these words or variations of such words, similar expressions, or comparable terminology are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. A further list and description of risks, uncertainties and other factors that could cause actual results or events to differ materially from the forward-looking statements that we make is included in the cautionary statements herein and in our other filings with the SEC, including those set forth under Part I, Item 1A, Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.*

*We have based the forward-looking statements included in this Quarterly Report on Form 10-Q on information available to us on the date of this quarterly report, and we assume no obligation to update any such forward-looking statements, other than as required by law. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.*

### **Overview**

Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our lead product candidate, pemvidutide (formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (“NASH”). In addition, we are developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. Except where the context indicates otherwise, references to “we,” “us,” “our,” “Altimmune” or the “Company” refer to the company and its subsidiaries.

### **Recent Business Update**

On October 24, 2023, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation to the investigation of pemvidutide for the treatment of NASH.

#### *Pemvidutide - IMPACT trial*

On August 1, 2023 we announced that we enrolled the first subject in the Phase 2b IMPACT trial evaluating the safety and efficacy of pemvidutide in subjects with NASH. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. The biopsy-driven trial is expected to enroll approximately 190 subjects with and without diabetes randomized 1:2:2 to receive either 1.2 mg, 1.8 mg pemvidutide or placebo weekly for 48 weeks. The key efficacy endpoints are NASH resolution and fibrosis improvement after 24 weeks of treatment, with subjects followed for an additional 24 weeks to a total of 48 weeks for assessment of safety and additional biomarker responses. Top-line results from this trial are expected in the first quarter of 2025.

*Pemvidutide - MOMENTUM trial*

On September 12, 2023, we announced the completion of dosing (last subject last dose) in our 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight. Topline results from this trial are expected in the fourth quarter of 2023.

On March 21, 2023 we announced the topline results from a Week 24 interim analysis of 160 subjects in our 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The MOMENTUM Phase 2 obesity trial is being conducted at 30 sites across the U.S. and enrolled 391 subjects with subjects randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise. A pre-specified interim analysis was conducted after the first 160 subjects received up to 24 weeks of treatment.

At Week 24, subjects receiving pemvidutide achieved mean weight losses of 7.3%, 9.4% and 10.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, with the placebo group experiencing a mean weight loss of 1.0% (efficacy estimand using a mixed model of repeated measures (“MMRM”) analysis). Approximately 50% of subjects achieved 10% or more weight loss and approximately 20% of subjects achieved 15% or more weight loss at Week 24 at the 1.8 mg and 2.4 mg doses. Robust reductions in waist circumference (a measure of visceral fat) and serum lipids were also observed, and clinically meaningful reductions in blood pressure were achieved without clinically significant increases in heart rate.

On March 21, 2023, we also announced the results of the 12-week Phase 1b safety trial of pemvidutide in subjects with type 2 diabetes. The Phase 1b trial, which was conducted to evaluate the safety profile of pemvidutide in overweight and obese subjects with type 2 diabetes, was comprised of 54 subjects randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 12 weeks.

Subjects receiving pemvidutide achieved mean weight losses of 4.4%, 6.1% and 7.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, over only 12 weeks of treatment, with the placebo group experiencing a mean weight gain of 0.8% (efficacy estimand using MMRM analysis).

*HepTcell*

On April 11, 2023, we announced the completion of enrollment in our Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (“CHB”). With the achievement of this milestone, data readout is planned for the first quarter of 2024.

The multicenter clinical trial, which is being conducted at 26 sites in North America, Europe and Southeast Asia, enrolled approximately 80 subjects with inactive CHB and low levels of hepatitis B surface antigen (“HBsAg”). Subjects were randomized 1:1 to HepTcell or placebo. The primary endpoint of the trial is clinical response, defined as a 1-log or greater reduction or clearance in HBsAg. Secondary endpoints include changes in the levels of hepatitis B virus (“HBV”) DNA, pre-genomic RNA and other markers of virologic response.



**Results of Operations**

**Comparison of the three months ended September 30, 2023 and 2022**

The following table summarizes our results of operations for the three months ended September 30, 2023 and 2022 (in thousands):

	Three Months Ended			
	2023	2022	September 30,	
			Increase (Decrease)	
Revenue	\$ 362	\$ 2	\$ 360	18,000 %
Operating expenses:				
Research and development	18,388	20,262	(1,874)	(9)%
General and administrative	4,514	4,492	22	0 %
Total operating expenses	22,902	24,754	(1,852)	(7)%
Loss from operations	(22,540)	(24,752)	2,212	(9)%
Other income (expense):				
Interest expense	(29)	(64)	35	(55)%
Interest income	1,884	1,053	831	79 %
Other income (expense), net	14	50	(36)	(72)%
Total other income (expense), net	1,869	1,039	830	80 %
Net loss before income taxes	(20,671)	(23,713)	3,042	(13)%
Income tax expense (benefit)	—	(197)	197	(100)
Net loss	\$ (20,671)	\$ (23,516)	\$ 2,845	(12)%

*Revenue*

We have not generated any revenues from the sale of any products to date. Our revenue has historically consisted primarily of government and foundation grants and contracts that supported our efforts on specific research projects. We are closing out one such contract and any revenue reported during the three months ended September 30, 2023 and 2022 were for indirect rate adjustments.

*Research and development expenses*

Research and development expenses decreased by \$1.9 million, or 9%, for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The decrease was primarily the result of:

- a decrease of \$3.5 million due to the development activities for pemvidutide primarily due to \$5.5 million in expenses associated with the NAFLD trials and \$1.3 million in expenses associated with Phase 1 safety trials, which were ongoing during the three months ended September 30, 2022, being substantially completed by March 31, 2023, and a \$1.8 million reduction due to winding down of MOMENTUM Phase 2 trial, partially offset by \$2.3 million in startup costs related to the IMPACT Phase 2b trial in NASH and a \$2.8 million increase in net manufacturing expenses for production of Good Manufacturing Practice (“GMP”) drug substance materials;
- a decrease of \$0.2 million due to development activities for HepTcell; and
- a net increase of \$1.9 million due primarily to costs associated with non-project specific research and development costs such as \$1.2 million for employee compensation including stock compensation, \$0.2 million for contractors and \$0.3 million for electronic document management system (“EDMS”) implementation and service costs.

*General and administrative expenses*

General and administrative expenses were consistent period-over-period at \$4.5 million for the three months ended September 30, 2023 and 2022.

*Total other income (expense), net*

Total other income (expense), net increased by \$0.8 million or 80%, for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022, primarily due to increase in interest income earned on our cash equivalents and short-term investments.

*Income tax benefit*

Income tax benefit of \$0.2 million related to interest received and receivable on income tax refunds was recorded during the three months ended September 30, 2022. Other than the income tax benefit related to interest, we did not record an income tax expense (benefit) for the three months ended September 30, 2023 and 2022 due to a full valuation allowance.

**Comparison of the nine months ended September 30, 2023 and 2022**

The following table summarizes our results of operations for the nine months ended September 30, 2023 and 2022 (in thousands):

	Nine Months Ended September 30,			
	2023	2022	Increase (Decrease)	
Revenue	\$ 389	\$ 42	\$ 347	826 %
Operating expenses:				
Research and development	48,890	51,359	(2,469)	(5)%
General and administrative	13,805	13,329	476	4 %
Total operating expenses	62,695	64,688	(1,993)	(3)%
Loss from operations	(62,306)	(64,646)	2,340	(4)%
Other income (expense):				
Interest expense	(33)	(191)	158	(83)%
Interest income	5,387	1,402	3,985	284 %
Other income (expense), net	146	185	(39)	(21)%
Total other income (expense), net	5,500	1,396	4,104	294 %
Net loss before income taxes	(56,806)	(63,250)	6,444	(10)%
Income tax expense (benefit)	—	(197)	197	(100)
Net loss	\$ (56,806)	\$ (63,053)	\$ 6,247	(10)%

*Revenue*

We have not generated any revenues from the sale of any products to date. Our revenue has historically consisted primarily of government and foundation grants and contracts that supported our efforts on specific research projects. We are closing out one such contract and any revenue reported during the nine months ended September 30, 2023 and 2022 were for indirect rate adjustments.

*Research and development expenses*

Research and development expenses decreased by \$2.5 million, or 5%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The decrease was primarily the result of:

- a decrease of \$8.0 million due to the development activities for pemvidutide primarily due to \$11.5 million in expenses associated with the NAFLD trials and \$5.5 million in expenses associated with Phase 1 safety trials, which were ongoing during the nine months ended September 30, 2022, being substantially completed by March 31, 2023, partially offset by \$4.1 million in startup costs related to the IMPACT Phase 2b trial in NASH, a \$1.9 million increase in net manufacturing expenses for production of GMP drug substance materials and \$3.0 million for the MOMENTUM Phase 2 trial, which began in September 2022 and completed dosing in September 2023; and

- a net increase of \$5.5 million due primarily to costs associated with non-project specific research and development costs such as \$4.2 million for employee compensation including stock compensation, \$0.6 million for contractors and \$0.8 million for EDMS implementation and service costs.

#### *General and administrative expenses*

General and administrative expenses increased by \$0.5 million, or 4% for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, primarily due to a \$0.4 million increase in stock compensation and other labor related expense.

#### *Total other income (expense), net*

Total other income (expense), net increased by \$4.1 million or 294%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, primarily due to increase in interest income earned on our cash equivalents and short-term investments.

#### *Income tax benefit*

Income tax benefit of \$0.2 million related to interest received and receivable on income tax refunds was recorded during the nine months ended September 30, 2022. Other than the income tax benefit related to interest, we did not record an income tax expense (benefit) for the nine months ended September 30, 2023 and 2022 due to a full valuation allowance.

### ***Liquidity and Capital Resources***

#### *Overview*

Our primary sources of cash during the nine months ended September 30, 2023 were from equity transactions, interest and dividends from our money market funds and short-term investments, and proceeds from maturity of our short-term investments. Our cash, cash equivalents, restricted cash and short-term investments were \$140.8 million as of September 30, 2023. We believe, based on the operating cash requirements and capital expenditures expected for 2023 and 2024, our cash on hand as of September 30, 2023, together with expected cash receipts from our income tax refunds and R&D incentives, are sufficient to fund operations for at least a twelve-month period from the issuance date of our September 30, 2023 consolidated financial statements.

We have not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales. In the past, our sources of revenue have consisted of grant revenues under our arrangements with BARDA for the development of NasoShield, MTEC for a clinical trial and development work on T-COVID, and to a lesser degree from other licensing arrangements. The MTEC contract was closed out in June 2021 and we are currently closing out the BARDA contract which was not renewed after December 31, 2021. We have incurred significant losses since we commenced operations. As of September 30, 2023, we had an accumulated deficit of \$434.7 million. In addition, we have not generated positive cash flows from operations. We have had to rely on a variety of financing sources, including the issuance of debt and equity securities. As capital resources are consumed to fund our research and development activities, we may require additional capital beyond our currently anticipated amounts. In order to address our capital needs, including our planned clinical trials, we must continue to actively pursue additional equity or debt financing, government funding, and monetization of our existing programs through partnership arrangements or sales to third parties.

#### ***Sources of Liquidity***

##### *Public Offering*

On July 16, 2020, we offered and sold (i) 3,369,564 shares of our common stock, at a price to the public of \$23.00 per share, and (ii) Pre-Funded Warrants, at a price to the public of \$22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of common stock, minus the exercise price of each Pre-

Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of our common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our common stock then issued and outstanding, which percentage may change at the holders' election to any other number less than or equal to 19.99% upon 61 days' notice to us. The gross proceeds of this offering were approximately \$132.2 million, which includes the exercise in full of the underwriters' option to purchase an additional 750,000 shares of common stock, before deducting underwriting discounts and commissions and offering expenses during the third quarter of 2020. The net proceeds of this offering were approximately \$124.0 million, after deducting underwriting discounts and commissions and offering expenses payable by us. On January 24, 2022, 760,870 of the Pre-Funded Warrants were exercised, resulting in the issuance of 760,870 shares of common stock. The remaining 869,566 Pre-Funded Warrants were net cashless exercised on October 18, 2023, resulting in the issuance of 869,530 shares of common stock (see Note 11 Subsequent Events).

#### *Shelf Registrations*

On February 28, 2023, we filed a shelf registration statement on Form S-3ASR, which was declared effective immediately. This shelf registration allows us to offer and sell any amount of our common stock, preferred stock, debt securities, warrants, rights and units (the "2023 Shelf") for a period of 3 years from effectiveness or until such determination that we no longer qualify as a well-known seasoned issuer.

On December 31, 2020, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on January 11, 2021. This shelf registration statement covered the offering, issuance and sale by us of up to an aggregate of \$250.0 million of our common stock, preferred stock, debt securities, warrants, rights and units (the "2021 Shelf").

#### *At-the-Market Offerings*

On February 28, 2023, we entered an Equity Distribution Agreement ("the 2023 Agreement") with Evercore Group L.L.C., JMP Securities LLC and B. Riley Securities, Inc., serving as sales agents, with respect to an at-the-market offerings program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to \$150.0 million. During the nine months ended September 30, 2023, we sold 3,536,284 shares of common stock under the 2023 Agreement resulting in approximately \$13.9 million in net proceeds, and as of September 30, 2023, \$135.7 million remained available to be sold under the 2023 Shelf.

On February 25, 2021, we entered into an Equity Distribution Agreement (the "2021 Agreement") with Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents, with respect to an at-the-market offerings program under which we offered and sold shares of our common stock, having an aggregate offering price of up to \$125.0 million. Under the 2021 Agreement, we sold 10,004,869 shares of common stock resulting in approximately \$121.0 million in proceeds, net of \$4.0 million commission and other offering costs. As of September 30, 2023, there were no remaining 2021 Shares available under the 2021 Agreement.

#### *Cash Flows*

The following table provides information regarding our cash flows for the nine months ended September 30, 2023 and 2022:

<i>(in thousands)</i>	Nine Months Ended September 30,	
	2023	2022
Net cash (used in) provided by:		
Operating activities	\$ (59,277)	\$ (45,280)
Investing activities	21,691	(74,380)
Financing activities	13,351	56,824
Net decrease in cash and cash equivalents and restricted cash	<u>\$ (24,235)</u>	<u>\$ (62,836)</u>

### *Operating Activities*

Net cash used in operating activities was \$59.3 million for the nine months ended September 30, 2023 compared to \$45.3 million during the nine months ended September 30, 2022. The primary uses of cash from our operating activities include payments for labor and labor-related costs, professional fees, research and development costs associated with our clinical trials and other general corporate expenditures. The increase in cash used in operations of \$14.0 million year over year is due to changes in working capital accounts of \$20.7 million, partially offset by an increase in net loss as adjusted for non-cash items of \$6.7 million.

### *Investing Activities*

Net cash provided by investing activities was \$21.7 million for the nine months ended September 30, 2023 compared to \$74.4 million net cash used in during the nine months ended September 30, 2022. The net cash provided by investing activities during the nine months ended September 30, 2023 was primarily due to \$76.5 million proceeds from sale and maturities of short-term investments, partially offset by \$54.8 million purchase of short-term investments. The net cash used in investing activities during the nine months ended September 30, 2022 was primarily due to \$74.3 million purchase of short-term investments.

### *Financing Activities*

Net cash provided by financing activities during the nine months ended September 30, 2023 was \$13.4 million compared to \$56.8 million for the nine months ended September 30, 2022. The net cash provided by financing activities during the nine months ended September 30, 2023 was primarily the result of the receipt of \$13.9 million in net proceeds from the issuance of common stock from our at-the-market offerings program, partially offset by \$0.5 million payment for tax withholding obligations related to share-based compensation and \$0.2 million payment for deferred offering costs. The net cash provided by financing activities during the nine months ended September 30, 2022 was primarily the result of the receipt of \$56.2 million in proceeds from the issuance of common stock from our at-the-market offerings program and \$0.9 million in proceeds from exercise of stock options, partially offset by \$0.4 million payment for tax withholding obligations related to share-based compensation.

### *Current Resources*

We have financed our operations to date principally through our equity offerings and proceeds from issuances of our preferred stock, common stock and warrants. As of September 30, 2023, we had \$86.9 million of cash, cash equivalents and restricted cash and \$53.9 million of short-term investments. Accordingly, management believes that we have sufficient capital to fund our plan of operations for at least a twelve-month period from the issuance date of our September 30, 2023 financial statements. However, in order to address our capital needs in the long-term, including our planned clinical trials, we must continue to actively pursue additional equity or debt financing, government funding, and monetization of our existing programs through partnership arrangements or sales to third parties.

### *Critical Accounting Estimates*

Management's Discussion and Analysis of Financial Condition and Results of Operations is based upon our unaudited consolidated financial statements, which have been prepared in accordance with U.S. GAAP and the rules and regulations of the SEC for interim financial reporting. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and the disclosure of contingent liabilities in our consolidated financial statements. We base our estimates and judgments on historical experience, knowledge of current conditions, and expectations of what could occur in the future given available information.

There have been no changes in our critical accounting policies and significant judgment and estimates as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, except for the recently adopted accounting standard for ASU No. 2016-13 as disclosed in Note 2. For more information regarding our critical accounting policies, we encourage you to read the discussion contained in Item 7 under the heading "Critical Accounting Estimates" and Note 2

“Summary of Significant Accounting Policies” included in the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.

### **Item 3. Quantitative and Qualitative Disclosures about Market Risk**

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide the information required by this Item.

### **Item 4. Controls and Procedures**

#### **Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (“the “Exchange Act”) as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of September 30, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

#### **Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2023 identified in connection with the evaluation thereof by our management, including the Chief Executive Officer and Chief Financial Officer, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## **PART II. OTHER INFORMATION**

### **Item 1. Legal Proceedings**

From time to time, we may be involved in various legal proceedings arising from the normal course of business activities. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

#### **Item 1A. Risk Factors**

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on February 28, 2023.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

### **Item 3. Default upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None.

**Item 6. Exhibits**

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
3.1	<a href="#">Amended and Restated Certificate of Incorporation, dated October 17, 2017 (incorporated by reference to Exhibit 3.1 to the Registrant's Form 8-K filed on October 18, 2017)</a>
3.2	<a href="#">Certificate of Amendment to Amended and Restated Certificate of Incorporation regarding a reverse stock split (incorporated by reference to Exhibit 3.1 to the Registrant's Form 8-K filed on September 13, 2018)</a>
3.3	<a href="#">Certificate of Amendment to Amended and Restated Certificate of Incorporation regarding an increase in authorized shares (incorporated by reference to Exhibit 3.2 to the Registrant's Form 8-K filed on September 13, 2018)</a>
3.4	<a href="#">Amended and Restated Bylaws of Altimmune, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant's Form 8-K filed on October 18, 2017)</a>
31.1 †	<a href="#">Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)</a>
31.2 †	<a href="#">Certification of Principal Financial Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)</a>
32.1 †	<a href="#">Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code</a>
32.2 †	<a href="#">Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code</a>
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

---

† This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

§ Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

ALTIMMUNE, INC.

Dated: November 7, 2023

By: /s/ Vipin K. Garg  
Name: Vipin K. Garg  
Title: President and Chief Executive Officer (Principal Executive Officer)

Dated: November 7, 2023

By: /s/ Richard Eisenstadt  
Name: Richard Eisenstadt  
Title: Chief Financial Officer (Principal Financial and Accounting Officer)

**Certification of Principal Executive Officer  
Pursuant to SEC Rule 13a-14(a)/15d-14(a)**

I, Vipin K. Garg, certify that:

1. I have reviewed this report on Form 10-Q of Altimmune, Inc. for the period ended September 30, 2023;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 7, 2023

/s/ Vipin K. Garg

Name: Vipin K. Garg

Title: President and Chief Executive Officer

(Principal Executive Officer)

---

**Certification of Principal Financial Officer  
Pursuant to SEC Rule 13a-14(a)/15d-14(a)**

I, Richard Eisenstadt, certify that:

1. I have reviewed this report on Form 10-Q of Altimmune, Inc. for the period ended September 30, 2023;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 7, 2023

/s/ Richard Eisenstadt

\_\_\_\_\_  
Name: Richard Eisenstadt  
Title: Chief Financial Officer  
(Principal Financial Officer)

---

**Certification Pursuant to Section 1350 of Chapter 63  
of Title 18 of the United States Code**

In connection with the quarterly report on Form 10-Q of Altimune, Inc. (the "Company") for the period ended September 30, 2023, as filed with the Securities and Exchange Commission (the "Report"), I, Vipin K. Garg, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Vipin K. Garg

Vipin K. Garg

President and Chief Executive Officer

November 7, 2023

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

---

**Certification Pursuant to Section 1350 of Chapter 63  
of Title 18 of the United States Code**

In connection with the quarterly report on Form 10-Q of Altimune, Inc. (the "Company") for the period ended September 30, 2023, as filed with the Securities and Exchange Commission (the "Report"), I, Richard Eisenstadt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard Eisenstadt

---

Richard Eisenstadt  
Chief Financial Officer  
November 7, 2023

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

---